NuView Life Sciences Secures $90M for NV-VPAC1 Cancer Portfolio
NuView Life Sciences will use the funds to complete a 600-patient in vitro double-blind clinical trial for the NV-VPAC1 cancer portfolio.
Read More
Search Results for: prostate cancer
Medicare Expands Coverage for BRACAnalysis CDx in Prostate Cancer
Medicare expanded coverage for BRACAnalysis CDx for men with prostate cancer who are eligible or may become eligible for treatment with Lynparza (olaparib).
Read More
miR Scientific Noninvasive Prostate Cancer Test Validation Published
miR Scientific’s urine-based, noninvasive cancer test can detect molecular evidence of prostate cancer with sensitivity of 94% and specificity of 92%.
Read More
Liquid Biopsy Research Reveals New Insights on Genetic Changes in Cancer
Researchers used Menarini Silicon Biosystems’ liquid biopsy technology to learn more about genetic changes in circulating cancer cells.
Read More
Mir Scientific Named Finalist in Fierce Innovation Awards
Mir Scientific is a Fierce Innovation Awards finalist for its liquid biopsy urine test that can accurately detect and grade prostate cancer noninvasively.
Read More